by Andrew Brown, PhD

Antibody-drug conjugates have moved from concept to a proven therapeutic class. With more than 15 FDA-approved ADCs and a pipeline of over 100 candidates in active clinical development, ADCs represent one of the fastest-growing segments of the oncology pipeline. The momentum is driven by a simple but powerful idea: deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue.

The clinical impact is already reshaping how we think about target expression. The approval of trastuzumab deruxtecan (Enhertu^®) for HER2-low breast cancer demonstrated that a patient population previously considered HER2-negative could respond to ADC therapy when target expression was characterized with greater sensitivity. It was a turning point: the biology hadn’t changed, but the precision of measurement had.

In practical terms, building a successful ADC is complex. These are multi-component therapies where the antibody, linker, payload, and their metabolites all contribute independently to safety, efficacy, and pharmacokinetics. Recognizing this complexity, the FDA issued its first dedicated guidance on clinical pharmacology considerations for ADCs in March 2024, providing developers with a structured framework for evaluating these therapies throughout clinical development.

For biomarker and translational science teams, this guidance has significant implications. It raises the bar on how thoroughly ADC components should be characterized, and it creates new opportunities for spatial biology and single cell technologies to address questions that conventional analytical approaches struggle to answer.

What the FDA Guidance Recommends

The March 2024 guidance (FDA-2021-D-1051) addresses clinical pharmacology across six core areas: bioanalytical methods, dosing strategies, dose and exposure-response analysis, intrinsic factors, QTc assessment, immunogenicity, and drug-drug interactions.

The central principle is that ADCs should be evaluated as multi-component products. The guidance recommends that sponsors measure the intact conjugate, the total antibody, the unconjugated payload, and relevant metabolites using validated assays throughout development. If any component is excluded from the bioanalytical strategy, the guidance advises sponsors to provide clear scientific justification.

Tw areas are particularly relevant for biomarker and translational teams:

Target Expression and Heterogeneity

The guidance recommends that sponsors characterize target antigen expression as part of the dose-response evaluation. For ADCs, this goes beyond simple positive/negative scoring. The FDA’s current thinking implies a need to understand expression levels, distribution patterns, and heterogeneity across tumor and normal tissues, because these factors directly influence ADC binding, internalization, and therapeutic index.

The clinical relevance of expression heterogeneity is increasingly well-documented. Beyond the HER2-low example, targets like Nectin-4 in urothelial carcinoma and Trop-2 across multiple solid tumor types show significant intra-tumoral and inter-patient expression variability that directly affects ADC efficacy. Understanding this variability requires characterization methods that go beyond binary scoring.

This is where conventional immunohistochemistry reaches its limits. A single chromogenic IHC stain can tell you whether a target is present, but it cannot simultaneously characterize the spatial relationship between target-expressing cells, immune infiltrates, and stromal architecture. Understanding these relationships is increasingly recognized as essential for predicting ADC efficacy, particularly for targets with heterogeneous expression patterns.

Tumor Microenvironment Characterization

ADC efficacy does not occur in isolation. The tumor microenvironment modulates immune response, affects drug penetration, and influences bystander killing, where cytotoxic payloads released from target-positive cells affect neighboring target-negative cells. The FDA’s emphasis on dose-response characterization and intrinsic factors implicitly calls for deeper understanding of the biological context in which ADCs operate.

The bystander effect is a spatial phenomenon at its core. The radius of payload diffusion from a dying target-positive cell determines which neighboring cells are affected, and that radius depends on physical distances within intact tissue that can only be quantified through spatially resolved imaging. Published data increasingly suggest that the density and spatial arrangement of target-positive cells relative to target-negative populations predict bystander killing efficiency more accurately than bulk expression measurements alone.

Spatial biology technologies enable simultaneous profiling of 40 or more markers within intact tissue sections, revealing how target expression, immune cell infiltration, and stromal organization interact at the cellular and subcellular level. This level of resolution is becoming essential for understanding why ADCs that show strong activity in cell-line models sometimes underperform in clinical settings where TME complexity comes into play.

Figure 1: Spatial Biology Applications Across the FDA ADC Guidance Framework

Where Spatial Biology Adds Value

The FDA guidance does not prescribe specific technologies. But the depth of characterization it recommends, particularly around target expression, TME profiling, and exposure-response relationships, aligns with the information multiplexed spatial biology and single cell technologies enable.

Multiplexed target characterization. Highly multiplexed tissue imaging enables simultaneous assessment of the ADC target alongside immune markers, stromal markers, and functional markers within the same tissue section. This provides the kind of integrated, spatially resolved data that supports more nuanced dose-response analysis than serial single-marker IHC.

Spatial immune profiling for bystander effect assessment. Understanding the spatial proximity between target-positive tumor cells and neighboring immune or stromal populations helps predict bystander killing dynamics. Spatial biology quantifies these distance relationships directly from tissue, providing data that complements traditional pharmacokinetic modeling with the actual tissue architecture where ADC activity occurs.

Single cell resolution for heterogeneity analysis. Mass cytometry and spectral flow cytometry enable deep immunophenotyping at the single cell level, characterizing 40 + markers simultaneously. When paired with spatial tissue analysis, this creates a comprehensive picture of both circulating and tissue-resident cell populations relevant to ADC activity.

Pharmacodynamic biomarker development. Longitudinal spatial analysis of pre-treatment and on-treatment biopsies can identify biomarker signatures associated with response or resistance. These signatures become candidate pharmacodynamic endpoints that support the exposure-response analysis the guidance recommends.

Practical Implications for ADC Development Programs

For teams implementing ADC clinical programs, the guidance points to several actionable considerations:

Develop biomarker strategy early. The guidance’s emphasis on multi-component characterization means bioanalytical and biomarker planning needs to start in preclinical development, not at the Phase 2 stage. Early integration of spatial and single cell readouts into the biomarker strategy strengthens IND submissions and reduces regulatory risk.

Invest in multiplexed tissue characterization. Single-marker IHC is increasingly insufficient. Harnessing multiplexed spatial platforms provides richer data from the same tissue samples, which is particularly valuable when biopsy material is limited.

Connect biomarker data to clinical pharmacology. The guidance explicitly links biomarker characterization to dose-response and exposure-response analysis. Biomarker teams should work closely with clinical pharmacology to ensure spatial and single cell data feeds directly into PK/PD modeling and dosing strategy.

Plan for regulatory-grade data. Exploratory biomarker data generated in non-accredited settings may not satisfy regulatory expectations. Working with laboratories that hold both GCLP and CLIA accreditation ensures biomarker data meets the quality standards regulators expect. GCLP (Good Clinical Laboratory Practice) provides an additional quality framework specifically designed for clinical trial laboratory operations, covering pre-analytical sample handling through post-analytical reporting in ways that CLIA alone does not address. This is particularly important for assays supporting primary or secondary clinical endpoints, where data integrity requirements are most stringent.

Looking Ahead

The ADC field is evolving rapidly, and each emerging modality intensifies the need for spatially resolved, multi-parameter tissue characterization:

Bispecific ADCs targeting two antigens simultaneously necessitates spatial co-expression analysis to identify patients whose tumors express both targets in therapeutically relevant patterns and proximity.

Conditionally activated ADCs designed to cleave only within the tumor microenvironment will need spatial profiling of the activation conditions (pH, enzyme expression, hypoxia) that determine where payload release occurs in tissue.

Immune-stimulating ADC payloads that combine cytotoxic killing with immune activation will require integrated spatial and single cell characterization of both tumor cell death and the resulting immune response within the TME.

The FDA’s 2024 guidance establishes a framework that ADC developers will build on for years to come. Teams that integrate spatial biology and single cell technologies into their biomarker strategies now will be better positioned to meet regulatory expectations and will develop ADCs that work for the right patients.

Learn how Sirona Dx’s spatial biology and single cell services can support your ADC development program →

References

1. FDA. Clinical Pharmacology Considerations for Antibody-Drug Conjugates: Guidance for Industry. March 2024. Docket Number FDA-2021-D-1051.
2. FDA. Guidance Recap Podcast: Clinical Pharmacology Considerations for Antibody-Drug Conjugates. 2024.
3. Tarantino P, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165-182.
4. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
5. Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20.
6. Schmid P, et al. Spatial analysis of the tumor microenvironment in antibody-drug conjugate-treated tumors: implications for patient stratification. J Clin Oncol. 2024;42(suppl).
7. Drago JZ, et al. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344.

About the Author

Andrew Brown, PhD, has extensive experience in spatial multi omics and tumor microenvironment analysis and assists clients through the design and implementation of complex biomarker programs spanning spatial biology, single cell proteomics, and immune monitoring. At Sirona Dx, he works closely with biopharma partners and the broader Sirona Dx team to translate advanced spatial and single cell technologies into actionable insights that accelerate therapeutic development.